DK2076532T3 - Cytokinderivater - Google Patents

Cytokinderivater

Info

Publication number
DK2076532T3
DK2076532T3 DK07825334.1T DK07825334T DK2076532T3 DK 2076532 T3 DK2076532 T3 DK 2076532T3 DK 07825334 T DK07825334 T DK 07825334T DK 2076532 T3 DK2076532 T3 DK 2076532T3
Authority
DK
Denmark
Prior art keywords
terminal portion
cytokine derivatives
cytokine
derivatives
polypeptides
Prior art date
Application number
DK07825334.1T
Other languages
Danish (da)
English (en)
Inventor
Oliver Hartley
Original Assignee
Mintaka Foundation For Medical Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mintaka Foundation For Medical Res filed Critical Mintaka Foundation For Medical Res
Application granted granted Critical
Publication of DK2076532T3 publication Critical patent/DK2076532T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/521Chemokines
    • C07K14/523Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
DK07825334.1T 2006-07-25 2007-07-25 Cytokinderivater DK2076532T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0614755.7A GB0614755D0 (en) 2006-07-25 2006-07-25 Cytokine derivatives
PCT/IB2007/003026 WO2008012689A2 (en) 2006-07-25 2007-07-25 Cytokine derivatives

Publications (1)

Publication Number Publication Date
DK2076532T3 true DK2076532T3 (da) 2011-03-07

Family

ID=37006114

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07825334.1T DK2076532T3 (da) 2006-07-25 2007-07-25 Cytokinderivater

Country Status (25)

Country Link
US (2) US8686111B2 (https=)
EP (1) EP2076532B1 (https=)
JP (1) JP5224603B2 (https=)
KR (1) KR101530353B1 (https=)
CN (1) CN101511867B (https=)
AT (1) ATE490270T1 (https=)
AU (1) AU2007278894B2 (https=)
BR (1) BRPI0715331B8 (https=)
CA (1) CA2658806C (https=)
CY (1) CY1111630T1 (https=)
DE (1) DE602007010969D1 (https=)
DK (1) DK2076532T3 (https=)
ES (1) ES2361455T3 (https=)
GB (1) GB0614755D0 (https=)
HR (1) HRP20110146T1 (https=)
ME (1) ME01320B (https=)
MX (1) MX2009000918A (https=)
NZ (1) NZ575092A (https=)
PL (1) PL2076532T3 (https=)
PT (1) PT2076532E (https=)
RS (1) RS51854B (https=)
RU (1) RU2461567C2 (https=)
SI (1) SI2076532T1 (https=)
WO (1) WO2008012689A2 (https=)
ZA (1) ZA200901342B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201600091033A1 (it) * 2016-09-08 2018-03-08 Bioimmunizer Sagl Ceppi di batteri probiotici appartenenti al genere Bifidobacterium e loro estratti di cellule probiotiche (ECP) aventi proprietà immunostimolanti.
KR20210016398A (ko) * 2018-05-28 2021-02-15 오리온 바이오테크놀로지 스윗졀랜드 에스아에흐엘 암 치료에 사용하기 위한 ccr5 억제제
CN112469430B (zh) * 2018-05-28 2024-12-24 日内瓦大学 抑制大脑炎症的方法
EP4646232A1 (en) 2023-01-06 2025-11-12 Université de Genève Variant ligand conjugates for payload delivery
WO2025172252A1 (en) 2024-02-15 2025-08-21 Novo Nordisk A/S Protracted ccr5 antagonists and uses thereof
WO2025176787A1 (en) 2024-02-22 2025-08-28 Orion Biotechnology Holding Sa Ccl5 variants for modulating gpr75
WO2025186255A1 (en) 2024-03-06 2025-09-12 Orion Biotechnology Holding Sa Gipr inhibitors and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2164818C (en) * 1993-06-09 2003-09-23 Charles D.Y. Sia Tandem synthetic hiv-1 peptides
FR2748938B1 (fr) * 1996-05-22 1998-07-31 Pasteur Institut Utilisation de molecules antagonistes de chemokines pour leur activite antivirale notamment contre un retrovirus de type vih
UA77950C2 (en) 2000-10-04 2007-02-15 Applied Research Systems Use of mutants of cc chemokines for treatment of multiple sclerosis
US20030049603A1 (en) * 2001-09-05 2003-03-13 Guy Gorochov Methods for construction and screening of libraries of chemokine variants
US7442512B2 (en) * 2001-11-30 2008-10-28 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
WO2005112567A2 (en) 2004-05-03 2005-12-01 University Of Maryland Biotechnology Institute Vaginal microbicide

Also Published As

Publication number Publication date
HK1131162A1 (en) 2010-01-15
HRP20110146T1 (hr) 2011-06-30
ME01320B (me) 2013-12-20
BRPI0715331B8 (pt) 2021-05-25
US20090317363A1 (en) 2009-12-24
US20130330305A1 (en) 2013-12-12
JP2009544304A (ja) 2009-12-17
MX2009000918A (es) 2009-08-26
RU2461567C2 (ru) 2012-09-20
EP2076532A2 (en) 2009-07-08
DE602007010969D1 (de) 2011-01-13
WO2008012689A2 (en) 2008-01-31
BRPI0715331B1 (pt) 2021-04-13
CA2658806A1 (en) 2008-01-31
AU2007278894B2 (en) 2012-08-09
CA2658806C (en) 2017-01-03
SI2076532T1 (sl) 2011-06-30
KR101530353B1 (ko) 2015-06-26
PT2076532E (pt) 2011-03-02
WO2008012689A3 (en) 2008-05-08
US8686111B2 (en) 2014-04-01
KR20090060281A (ko) 2009-06-11
RU2009106436A (ru) 2010-08-27
ES2361455T3 (es) 2011-06-17
AU2007278894A1 (en) 2008-01-31
JP5224603B2 (ja) 2013-07-03
CN101511867B (zh) 2014-04-09
BRPI0715331A2 (pt) 2013-07-16
CY1111630T1 (el) 2015-10-07
NZ575092A (en) 2011-08-26
EP2076532B1 (en) 2010-12-01
RS51854B (sr) 2012-02-29
ATE490270T1 (de) 2010-12-15
ZA200901342B (en) 2010-11-24
US9328153B2 (en) 2016-05-03
CN101511867A (zh) 2009-08-19
GB0614755D0 (en) 2006-09-06
PL2076532T3 (pl) 2011-07-29

Similar Documents

Publication Publication Date Title
NZ600731A (en) Oxyntomodulin peptide analogue
NZ600690A (en) Fkbp-l and uses thereof
NZ627111A (en) Variants of activin iib receptor polypeptides and uses thereof
NZ600732A (en) Oxyntomodulin peptide analogue
IN2014CN02050A (https=)
EA201170878A1 (ru) Полипептиды с ксиланазной активностью
ATE417595T1 (de) Keratin-bindende polypeptide
HRP20090245T1 (en) Pyy agonists and uses thereof
EA201170879A1 (ru) Полипептиды с ксиланазной активностью
DK2076532T3 (da) Cytokinderivater
WO2007115837B1 (en) Combination of an anti-edb fibronectin domain antibody/ il2 fusion protein and a further small molecule
NZ593550A (en) ANTI-Siglec-15 ANTIBODY
NO20075927L (no) IL-21 varianter
NZ591612A (en) Prevention, treatment and diagnosis of p.gingivalis infection with peptides
MX2008009493A (es) Peptido novedoso y uso del mismo.
WO2010007144A3 (en) Mutated netrin-4 proteins, fragments thereof and their uses as drugs
DE602007004110D1 (de) Hausstaubmilbenallergen
NZ601647A (en) Variant hhip1 protein and methods and uses thereof
WO2010057242A3 (de) Vakzin
WO2008047370A3 (en) Compositions and methods for inducing angiogenesis
GEP20115196B (en) Neublastin variants
WO2006097432A3 (de) Keratin-biktdende desmoplakinpolypeptidsequenzen
DE602007006493D1 (de) Peptide mit proliferationshemmender wirkung
ATE441865T1 (de) Neue polypeptide zur in-vintro-isolierung und vorbeugung von infektionen mit legionella pneumophila
MY150639A (en) T cell adhesion molecule and antibody thereto